chmp6

Migration, Crosslink

📖

chmp6

active

wiki page Created: 2026-04-02T07:19:30 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-chmp6

📖 Wiki Page

gene2954 wordssynced 2026-04-02

chmp6

Charged Multivesicular Body Protein 6 (CHMP6)

<div class="infobox infobox-gene">
<div class="infobox-header">CHMP6 — Charged Multivesicular Body Protein 6</div>

| Attribute | Value |
|-----------|-------|
| Gene Symbol | CHMP6 |
| Full Name | Charged Multivesicular Body Protein 6 |
| Chromosome | 17q25.1 |
| NCBI Gene ID | 79170 |
| OMIM | 607986 |
| Ensembl ID | ENSG00000115183 |
| UniProt ID | Q96FY2 |
| Protein Class | ESCRT-III component |
| Molecular Weight | 23 kDa |
| Subcellular Location | Endosome, cytoplasm |
| Tissue Expression | Brain, lung, testis, liver |
</div>

Overview

CHMP6 (Charged Multivesicular Body Protein 6) is a core component of the ESCRT-III (Endosomal Sorting Complex Required for Transport-III) complex, which plays essential roles in multivesicular body (MVB) formation, autophagosome maturation, and lysosomal function. This gene encodes a protein that is crucial for cellular protein homeostasis and has been implicated in the pathogenesis of neurodegenerative diseases through its roles in [endosomal sorting](/mechanisms/endosomal-sorting), [autophagy](/mechanisms/autophagy), and [lysosomal function](/mechanisms/lysosomal-dysfunction) [@hanson2012][@lee2019].

Protein Structure and Function

Structural Features

CHMP6 is a 201-amino acid protein belonging to the CHMP (Charged Multivesicular Body Protein) family:

...

chmp6

Charged Multivesicular Body Protein 6 (CHMP6)

<div class="infobox infobox-gene">
<div class="infobox-header">CHMP6 — Charged Multivesicular Body Protein 6</div>

| Attribute | Value |
|-----------|-------|
| Gene Symbol | CHMP6 |
| Full Name | Charged Multivesicular Body Protein 6 |
| Chromosome | 17q25.1 |
| NCBI Gene ID | 79170 |
| OMIM | 607986 |
| Ensembl ID | ENSG00000115183 |
| UniProt ID | Q96FY2 |
| Protein Class | ESCRT-III component |
| Molecular Weight | 23 kDa |
| Subcellular Location | Endosome, cytoplasm |
| Tissue Expression | Brain, lung, testis, liver |
</div>

Overview

CHMP6 (Charged Multivesicular Body Protein 6) is a core component of the ESCRT-III (Endosomal Sorting Complex Required for Transport-III) complex, which plays essential roles in multivesicular body (MVB) formation, autophagosome maturation, and lysosomal function. This gene encodes a protein that is crucial for cellular protein homeostasis and has been implicated in the pathogenesis of neurodegenerative diseases through its roles in [endosomal sorting](/mechanisms/endosomal-sorting), [autophagy](/mechanisms/autophagy), and [lysosomal function](/mechanisms/lysosomal-dysfunction) [@hanson2012][@lee2019].

Protein Structure and Function

Structural Features

CHMP6 is a 201-amino acid protein belonging to the CHMP (Charged Multivesicular Body Protein) family:

N-terminal basic region: Membrane interaction domain
Central helical domain: Core structural element
C-terminal acidic region: Regulatory and interaction sites
Polymerization interface: Enables filament formation

ESCRT-III Complex

CHMP6 functions as part of the ESCRT-III complex:

CHMP1-5: Core ESCRT-III components
CHMP6: Specifically involved in MVB formation
VPS4: AAA ATPase that disassembles ESCRT-III
ALIX: Accessory protein linking ESCRT functions

Molecular Function

CHMP6 participates in several critical cellular processes:

Multivesicular Body Formation: Initiates inward budding of endosomal membranes

Cargo Sorting: Recognizes and packages ubiquitinated proteins into MVBs

Autophagosome Maturation: Facilitates fusion with lysosomes

Membrane Scission: Mediates vesicle release from parent membrane

Role in Neurodegeneration

Endosomal Dysfunction

CHMP6 is crucial for proper endosomal sorting:

Processes [amyloid precursor protein (APP)](/proteins/app) and its cleavage products
Controls trafficking of [tau](/proteins/tau) and [alpha-synuclein](/proteins/alpha-synuclein)
Prevents toxic protein accumulation
ESCRT dysfunction leads to endosomal trafficking defects in AD and PD

Autophagy Impairment

CHMP6 plays a key role in [autophagy](/mechanisms/autophagy):

Facilitates autophagosome-lysosome fusion
Required for proper degradation of damaged organelles
Involved in清除 of protein aggregates
Loss of CHMP6 leads to accumulation of autophagic vesicles

Lysosomal Dysfunction

Proper lysosomal function depends on CHMP6:

MVB-lysosome fusion requires ESCRT-III
Prevents lysosomal membrane permeabilization
Maintains lysosomal acidic pH
Dysfunction leads to ceroid/lipofuscin accumulation

Specific Disease Mechanisms

Alzheimer's Disease

Regulates amyloid-beta secretion and clearance
Controls tau secretion via exosomes
ESCRT dysfunction promotes amyloid plaque formation

Parkinson's Disease

Facilitates alpha-synuclein degradation
Prevents Lewy body formation
Protects dopaminergic neurons from protein toxicity

Signaling Pathway

Mermaid diagram (expand to render)

Expression Pattern

CHMP6 is expressed in various tissues:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | High (neurons, glia) |
| Lung | Moderate |
| Testis | Moderate |
| Liver | Low-moderate |
| Kidney | Low |

In the brain, CHMP6 is expressed in:

Neurons (especially cortical and hippocampal)
[Astrocytes](/cell-type- [Oligodendrocytes](/cell-types/oligodendrocytes)oglia
[Oligodendrocytes](/cell-types/oligodendrocytes)

Molecular Interactions

ESCRT Complex Partners

CHMP6 interacts with multiple ESCRT components:

CHMP4 (both isoforms)
CHMP5
CHMP2
VPS4
ALIX

Non-ESCRT Interactions

Autophagy-related proteins
Ubiquitin ligases
Trafficking adaptors

Therapeutic Implications

Targeting ESCRT Function

Modulating CHMP6 or ESCRT function represents a therapeutic approach:

| Strategy | Approach | Status |
|----------|----------|--------|
| ESCRT enhancement | Increase ESCRT expression | Research |
| VPS4 modulators | Stabilize ESCRT complexes | Development |
| Autophagy induction | Bypass ESCRT defects | Preclinical |
| Gene therapy | Deliver functional CHMP6 | Experimental |

Challenges

ESCRT has multiple essential cellular functions
Systemic modulation may cause adverse effects
Achieving neuronal specificity is difficult
Optimal timing of intervention unclear

Research Directions

Current areas of investigation include:

CHMP6 phosphorylation and its regulation

Structure-function relationships in ESCRT-III

Cell-type specific CHMP6 functions in neurons

ESCRT cross-talk with other trafficking pathways

Biomarker development for ESCRT dysfunction

Small molecule ESCRT modulators

Molecular Mechanisms

ESCRT-III Polymerization

CHMP6 exhibits unique polymerization dynamics:

Filament formation:

CHMP6 forms helical filaments on membrane surfaces
Polymerization is reversible and regulated
Filament thickness: ~10nm
Assembly requires membrane association

Membrane deformation:

Induces inward budding of endosomal membranes
Facilitates cargo sorting into forming vesicles
Works in concert with other ESCRT components

Autophagy Connections

CHMP6 intersects with autophagy through multiple mechanisms:

Autophagosome-lysosome fusion:

Required for completion of autophagy
Facilitates membrane tethering
Enables degradation of cargo

Selective autophagy:

Role in aggregate clearance
Organelle turnover
Bacterial degradation (xenophagy)

Traffic Regulation

CHMP6 coordinates multiple trafficking pathways:

Endosomal sorting:

Cargo recognition and sequestration
Ubiquitin-dependent sorting
Recycling vs degradation decisions

Lysosomal delivery:

MVB fusion machinery
Enzyme delivery
Membrane protein turnover

Signaling Networks

Interactions with Other Pathways

CHMP6 function integrates with cellular signaling:

mTOR signaling:

mTOR inhibition induces ESCRT activity
Nutrient sensing links to trafficking
Autophagy regulation connection

Ubiquitin system:

ESCRT recognizes ubiquitinated cargo
Deubiquitination before degradation
Coordination with proteasome

Phosphoinositide signaling:

PI3P distribution on endosomes
Membrane identity specification
ESCRT recruitment signals

ESCRT Complex Dynamics

The ESCRT system functions as an integrated unit:

| Component | Function | CHMP6 Interaction |
|-----------|----------|-------------------|
| ESCRT-0 | Cargo recognition | Upstream recruitment |
| ESCRT-I | Polymer formation | Co-assembly |
| ESCRT-II | Membrane deformation | Coordination |
| ESCRT-III | Membrane scission | Direct interaction |
| VPS4 | Complex disassembly | Recycling |

Therapeutic Approaches

Modulation Strategies

Upregulation approaches:

Increase CHMP6 expression
Enhance ESCRT assembly
Promote autophagic clearance

Inhibition strategies:

Block excessive trafficking
Modulate protein degradation
Reduce exosome release

Combination Therapies

CHMP6-targeted approaches combined with:

Autophagy enhancers
Proteasome modulators
Anti-aggregation strategies
Anti-inflammatory treatments

Delivery Challenges

Targeting neuronal ESCRT:

Blood-brain barrier penetration
Cell-type specificity
Avoiding systemic effects
Achieving therapeutic concentrations

Model Systems

Research Models

| Model System | Advantages | Limitations |
|--------------|------------|-------------|
| Yeast | Genetic tractability | Evolutionary distance |
| C. elegans | In vivo trafficking | Limited toolkit |
| Drosophila | Neuronal studies | Differences from humans |
| Mammalian cells | Physiological relevance | Complexity |
| iPSC neurons | Disease modeling | Variability |

Phenotypic Readouts

Cellular phenotypes:

MVB size and number
Autophagosome accumulation
Lysosomal function
Cargo trafficking kinetics

Organismal phenotypes:

Locomotor function
Neuronal survival
Lifespan
Behavioral outputs

Clinical Translation

Biomarker Potential

Diagnostic markers:

ESCRT component levels in CSF
Exosome profiles
Genetic variant testing

Progression markers:

Longitudinal biomarker tracking
Correlations with clinical measures
Treatment response indicators

Clinical Development

Current status:

No direct CHMP6 modulators in trials
ESCRT biology actively investigated
Gene therapy approaches emerging

Future directions:

Small molecule development
RNA-based therapeutics
Protein replacement approaches

CHMP6 in Neuronal Physiology

Synaptic Function

CHMP6 plays important roles in neuronal function beyond general trafficking:

Synaptic vesicle trafficking:

ESCRT components regulate synaptic vesicle release
Controls presynaptic protein turnover
Modulates neurotransmitter release kinetics

Postsynaptic function:

Regulates AMPA receptor endocytosis
Controls NMDA receptor trafficking
Affects dendritic spine morphology

Neuronal Protein Quality Control

CHMP6 is crucial for protein homeostasis in neurons:

Aggregate clearance:

Mediates selective autophagy of protein aggregates
Handles misfolded protein stress
Prevents toxic protein accumulation

Membrane protein turnover:

Controls synaptic receptor density
Regulates ion channel expression
Manages signaling complex turnover

CHMP6 in Specific Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

CHMP6 involvement in ALS:

Protein homeostasis:

Dysregulated in ALS models
Contributes to TDP-43 aggregation
Affects autophagy-lysosome pathway

Motor neuron vulnerability:

ESCRT deficits in motor neurons
Enhanced sensitivity to stress
Links to SOD1 pathology

Frontotemporal Dementia

CHMP6 in FTD:

TDP-43 pathology:

ESCRT dysfunction worsens TDP-43 aggregation
Similar mechanisms to ALS
Shared therapeutic targets

Huntington's Disease

CHMP6 in HD:

Mutant huntingtin clearance:

ESCRT helps clear mutant huntingtin
Autophagy impairment in HD
Potential therapeutic target

Structural Insights

Crystal Structure

Recent structural studies have revealed:

Key structural features:

N-terminal alpha-helical domain
Central core structure
C-terminal polymerization motif

Conformational changes:

Open and closed conformations
Polymerization-induced changes
Membrane interaction interfaces

Structure-Function Relationships

Understanding structure enables drug development:

Targetable interfaces
Allosteric sites
Polymerization inhibitors

Therapeutic Strategies

Direct Targeting

ESCRT enhancement:

Increase CHMP6 expression
Promote ESCRT assembly
Enhance autophagy

Indirect Approaches

Autophagy induction:

Bypass ESCRT defects
Enhance lysosomal function
Promote aggregate clearance

Gene Therapy

AAV-CHMP6 delivery
Cell-type specific expression
Regulated expression systems

Biomarker Development

Diagnostic Markers

ESCRT component levels in CSF
Exosome profiles
Genetic testing

Disease Progression

Longitudinal biomarker tracking
Treatment response indicators
Clinical correlation studies

Research Models

In Vitro Models

| Model | Applications | Advantages |
|-------|--------------|------------|
| HEK cells | Basic mechanisms | Easy to manipulate |
| Primary neurons | Neuronal function | Physiological |
| iPSC neurons | Disease modeling | Patient-specific |

In Vivo Models

Mouse models
Zebrafish models
Drosophila models

Clinical Translation

Current Status

No CHMP6-targeted therapies in clinical trials
Active basic research
Preclinical development ongoing

Challenges

ESCRT has multiple essential functions
Achieving neuronal specificity
Systemic vs. local delivery

Future Directions

Small molecule modulators
RNA-based therapies
Gene replacement approaches

Key Publications

[Hanson PI, Cashikar A. Multivesicular body morphogenesis (2012)](https://pubmed.ncbi.nlm.nih.gov/22831642/)

[Lee JA, Liu L, Gao FB. Autophagy defects in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31222865/)

[ESCRT system in endosomal trafficking (2016)](https://pubmed.ncbi.nlm.nih.gov/27241612/)

[Molecular mechanisms of MVB formation (2015)](https://pubmed.ncbi.nlm.nih.gov/26156463/)

[ESCRT-III: an endosomal sorting complex (2009)](https://pubmed.ncbi.nlm.nih.gov/19395677/)

[CHMP6 and ESCRT-III function in autophagy (2019)](https://pubmed.ncbi.nlm.nih.gov/30668932/)

[ESCRT-mediated autophagy mechanisms (2013)](https://pubmed.ncbi.nlm.nih.gov/23924655/)

[ESCRT-III in neuronal function (2014)](https://pubmed.ncbi.nlm.nih.gov/24823624/)

[CHMP6 as component of ESCRT-III (2015)](https://pubmed.ncbi.nlm.nih.gov/25824076/)

[Role of ESCRT in neuronal trafficking (2017)](https://pubmed.ncbi.nlm.nih.gov/28285859/)

CHMP6 in Synaptic Function

Synaptic Vesicle Trafficking

CHMP6 plays a crucial role in synaptic vesicle cycle optimization and protein turnover at presynaptic terminals. The endosomal sorting machinery regulates synaptic vesicle protein composition by controlling the trafficking of synaptic vesicle components through the multivesicular body pathway. This process ensures that aged or damaged synaptic vesicle proteins are targeted for degradation while functional components are recycled.

The regulation of synaptic vesicle trafficking by ESCRT-III involves:

Control of synaptic vesicle protein quality control
Modulation of synaptic vesicle pool size
Regulation of vesicle release probability
Management of synaptic vesicle replenishment

Postsynaptic Receptor Trafficking

At postsynaptic sites, CHMP6 contributes to AMPA receptor (AMPAR) and NMDA receptor (NMDAR) turnover. Proper receptor trafficking is essential for synaptic plasticity, learning, and memory. ESCRT-mediated endosomal sorting controls the surface expression of these receptors, which directly impacts synaptic strength and plasticity mechanisms.

The postsynaptic functions include:

AMPA receptor recycling and degradation
NMDA receptor subunit composition
Synaptic scaffolding protein turnover
Dendritic spine morphology maintenance

Neurotransmitter Release Dynamics

CHMP6 influences neurotransmitter release through multiple mechanisms:

Synaptic vesicle priming: ESCRT components regulate the availability of release-ready synaptic vesicles

Fusion site maintenance: Proper protein turnover ensures optimal active zone function

Release probability: Modulation of presynaptic protein composition affects release probability

Replenishment kinetics: Controls the rate of synaptic vesicle pool replenishment after release

CHMP6 and Protein Aggregation in Neurodegeneration

Aggregate Clearance Mechanisms

Protein aggregation is a hallmark of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS. CHMP6-mediated ESCRT function is critical for clearing misfolded proteins and preventing toxic aggregate formation.

The aggregate clearance pathway involves:

Recognition of ubiquitinated protein aggregates
Engulfment into double-membrane autophagosomes
Delivery to multivesicular bodies
Fusion with lysosomes for degradation

Specific Aggregation Pathways

Alzheimer's Disease:

Amyloid precursor protein (APP) processing and Aβ secretion
Tau protein clearance and exosome-mediated spread
BACE1 trafficking and amyloid plaque formation

Parkinson's Disease:

Alpha-synuclein degradation pathways
Lewy body formation prevention
Dopaminergic neuron survival mechanisms

ALS:

TDP-43 aggregation clearance
SOD1 mutant protein clearance
FUS protein homeostasis

Molecular Interactions Deep Dive

CHMP6 Structural Basis

The CHMP6 protein structure reveals several key functional elements:

N-terminal Membrane Interaction Domain:

Highly basic region that binds negatively charged phospholipids
Membrane curvature sensing capability
Initial recruitment to endosomal membranes

Central Helical Core:

Six alpha-helices forming a helical bundle
Dimerization interface for filament formation
Conformational changes upon polymerization

C-terminal Regulatory Region:

Acidic terminal tail regulates polymerization
Multiple phosphorylation sites for functional control
Interaction sites for accessory proteins

Polymerization Mechanism

CHMP6 polymerization follows a stepwise process:

Membrane recruitment: Basic N-terminus localizes to endosomal membrane

Nucleation: Initial CHMP6 dimers form on membrane surface

Filament extension: Addition of CHMP6 subunits extends filaments

Constriction: Filaments deform membrane for intralumenal vesicle formation

Disassembly: VPS4 ATPase disassembles CHMP6 filaments for recycling

CHMP6-CHMP4 Interactions

The interaction between CHMP6 and CHMP4 isoforms is crucial for ESCRT-III function:

CHMP6 can initiate polymerization while CHMP4 completes the process
Co-polymerization creates hybrid filaments with unique properties
The stoichiometry affects membrane deformation efficiency
Cross-talk allows regulation of multiple ESCRT functions

Therapeutic Development Strategies

Small Molecule Approaches

Several strategies are being developed to target CHMP6 function:

ESCRT Enhancers:

Compounds that promote ESCRT-III assembly
Stabilizers of functional ESCRT complexes
Promoters of autophagosome-lysosome fusion

VPS4 Modulators:

ATPase activity modulators
VPS4-CHMP6 interaction enhancers
ESCRT recycling promoters

Autophagy Inducers:

mTOR-independent autophagy activators
Lysosomal function enhancers
Autophagic flux promoters

Gene Therapy Vectors

AAV-mediated CHMP6 delivery represents a promising approach:

Serotypes with high neuronal tropism
Cell-type specific promoters for targeting
Regulated expression systems for safety
Combination with other ESCRT components

Combination Therapies

Effective neuroprotection may require multi-target approaches:

ESCRT enhancement with autophagy inducers
Proteasome modulators with anti-aggregation compounds
Anti-inflammatory agents with protein homeostasis enhancers
Neurotrophic factors with trafficking modulators

Biomarker and Diagnostic Development

Disease Biomarkers

CHMP6 and ESCRT dysfunction markers:

CSF ESCRT component levels
Exosome profiles reflecting endosomal function
Genetic variant testing for risk assessment
Protein aggregation markers in peripheral tissues

Progression Indicators

Monitoring disease progression through:

Longitudinal biomarker tracking in patient cohorts
Correlation with clinical measures
Treatment response indicators
Prediction of therapeutic outcomes

Research Model Systems

Cell Culture Models

| Model | Applications | Advantages |
|-------|--------------|------------|
| HEK293 | Basic mechanisms | Easy transfection |
| HeLa | Pathway studies | Well-characterized |
| Primary neurons | Neuronal function | Physiologically relevant |
| iPSC neurons | Disease modeling | Patient-specific |
| Astrocytes | Glial function | CNS context |

Animal Models

Zebrafish:

Transparent embryos for imaging
Rapid development
Motor neuron studies

Drosophila:

Powerful genetics
Synaptic function assays
Short lifespan

Mouse:

Mammalian physiology
Behavioral testing
Disease modeling

Phenotypic Readouts

Assessing CHMP6 function through:

Endosomal morphology analysis
Autophagic flux measurements
Protein turnover kinetics
Synaptic function tests
Behavioral assessments

Clinical Considerations

Patient Stratification

Identifying patients who may benefit from ESCRT-targeted therapies:

Genetic variants affecting ESCRT function
Biomarkers of ESCRT dysfunction
Disease stage considerations
Comorbidity factors

Therapeutic Windows

Determining optimal treatment timing:

Pre-symptomatic intervention
Early disease stages
Advanced disease considerations
Combination with disease-modifying therapies

Future Research Directions

Unresolved Questions

Key questions remaining in CHMP6 research:

What is the precise molecular function of CHMP6 in neurons?

How does CHMP6 dysfunction contribute to specific diseases?

What are the cell-type specific roles of CHMP6?

Can ESCRT function be safely enhanced therapeutically?

Emerging Approaches

New research directions include:

Single-cell proteomics to identify cell-type specific functions
Spatial transcriptomics to map CHMP6 expression in tissue
Cryo-EM structures of ESCRT-III assemblies
High-throughput screening for ESCRT modulators

External Links

[NCBI Gene: CHMP6](https://www.ncbi.nlm.nih.gov/gene/79170)
[UniProt: Q96FY2](https://www.uniprot.org/uniprot/Q96FY2)
[Ensembl: ENSG00000115183](https://www.ensembl.org/Human/Gene/Summary?g=ENSG00000115183)
[OMIM: 607986](https://www.omim.org/entry/607986)

Allen Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — Gene expression data
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — Gene expression in mouse brain
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell transcriptomics

References

[Hanson PI, Cashikar A. Multivesicular body morphogenesis (2012)](https://pubmed.ncbi.nlm.nih.gov/22831642/)

[Lee JA, Liu L, Gao FB. Autophagy defects in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31222865/)

[The ESCRT system in endosomal trafficking (2016)](https://pubmed.ncbi.nlm.nih.gov/27241612/)

[Molecular mechanisms of multivesicular body formation (2015)](https://pubmed.ncbi.nlm.nih.gov/26156463/)

[ESCRT-III: an endosomal sorting complex (2009)](https://pubmed.ncbi.nlm.nih.gov/19395677/)

[Carlson J, et al. CHMP6 and ESCRT-III function in autophagy (2019)](https://pubmed.ncbi.nlm.nih.gov/30668932/)

[Ghazi-Noori S, et al. Molecular mechanisms of ESCRT-mediated autophagy (2013)](https://pubmed.ncbi.nlm.nih.gov/23924655/)

[McEwen C, et al. ESCRT-III in neuronal function (2014)](https://pubmed.ncbi.nlm.nih.gov/24823624/)

[Kataoka M, et al. CHMP6, a component of ESCRT-III (2015)](https://pubmed.ncbi.nlm.nih.gov/25824076/)

[Escudero B, et al. The role of ESCRT in neuronal trafficking (2017)](https://pubmed.ncbi.nlm.nih.gov/28285859/)

[Hanson PI, et al. ESCRT-III in neuronal health and disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21422400/)

[MVB-lysosome fusion (2018)](https://pubmed.ncbi.nlm.nih.gov/29761944/)

[Endosomal sorting complex required for transport (2010)](https://pubmed.ncbi.nlm.nih.gov/20592743/)

[CHMP4-ESCRT-III in neurodevelopment (2014)](https://pubmed.ncbi.nlm.nih.gov/24703865/)

[Lysosomal dysfunction in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32025009/)

[ESCRT deficiency in neurons and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25901033/)

[Autophagosome maturation and ESCRT (2016)](https://pubmed.ncbi.nlm.nih.gov/27085472/)

[CHMP family and neurodegenerative disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23579433/)

[Membrane trafficking in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29476837/)

[Endocytic pathway in neuronal health (2021)](https://pubmed.ncbi.nlm.nih.gov/33901052/)

[ESCRT dysfunction in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29572669/)

Pathway Diagram

The following diagram shows the key molecular relationships involving chmp6 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

CHMP6

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-chmp6
kg_node_id	CHMP6
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c65cd03e7d18
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-chmp6'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

20

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

chmp6

chmp6

Overview

Protein Structure and Function

Structural Features

chmp6

Overview

Protein Structure and Function

Structural Features

ESCRT-III Complex

Molecular Function

Role in Neurodegeneration

Endosomal Dysfunction

Autophagy Impairment

Lysosomal Dysfunction

Specific Disease Mechanisms

Alzheimer's Disease

Parkinson's Disease

Signaling Pathway

Expression Pattern

Molecular Interactions

ESCRT Complex Partners

Non-ESCRT Interactions

Therapeutic Implications

Targeting ESCRT Function

Challenges

Research Directions

Molecular Mechanisms

ESCRT-III Polymerization

Autophagy Connections

Traffic Regulation

Signaling Networks

Interactions with Other Pathways

ESCRT Complex Dynamics

Therapeutic Approaches

Modulation Strategies

Combination Therapies

Delivery Challenges

Model Systems

Research Models

Phenotypic Readouts

Clinical Translation

Biomarker Potential

Clinical Development

CHMP6 in Neuronal Physiology

Synaptic Function

Neuronal Protein Quality Control

CHMP6 in Specific Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

Huntington's Disease

Structural Insights

Crystal Structure

Structure-Function Relationships

Therapeutic Strategies

Direct Targeting

Indirect Approaches

Gene Therapy

Biomarker Development

Diagnostic Markers

Disease Progression

Research Models

In Vitro Models

In Vivo Models

Clinical Translation

Current Status

Challenges

Future Directions

Key Publications

CHMP6 in Synaptic Function

Synaptic Vesicle Trafficking

Postsynaptic Receptor Trafficking

Neurotransmitter Release Dynamics

CHMP6 and Protein Aggregation in Neurodegeneration

Aggregate Clearance Mechanisms

Specific Aggregation Pathways

Molecular Interactions Deep Dive

CHMP6 Structural Basis

Polymerization Mechanism